Australian biotechnology company All G has self-affirmed Generally Recognised as Safe (GRAS) status for its recombinant human lactoferrin, a regulatory milestone for adult nutrition and supplement applications in the United States.
Why human lactoferrin
Lactoferrin is one of the most abundant bioactive proteins in breast milk, supporting iron regulation, immune defence and gut health from the earliest days of life.
The human form is the one the human gut and immune system evolved to recognise. All G points to four advantages:
- low allergy risk: as a human protein, it is not a cow’s milk allergen
- receptor match: it fits the human intestinal lactoferrin receptor
- breast milk-like digestion: in simulated digestion, it releases the same peptides as breast milk lactoferrin
- consumer acceptance: research shows high acceptance of human lactoferrin as an ingredient.
Closest match to breast milk
All G says its protein matches breast milk lactoferrin on two counts no other GRAS human lactoferrin does.
It carries the full cluster of four amino acids found in 94% of women, which drives bioactivity, whereas a less common variant has only three.
It is also produced with low iron saturation, as in breast milk.
“Think of a rowboat with four people. Lose one rower and the boat still moves, but pulls off balance and loses drive,” said Dr Jared Raynes, All G’s Chief Scientific Officer.
Performance data
In in-house, side-by-side tests against commercially available human lactoferrin, All G’s product delivered 2.2 times the antimicrobial potency against a standard E. coli strain, 1.3 times stronger heparin binding and 2.3 times higher iron-binding capacity.
The company says that results align closely with native breast milk lactoferrin and further trials are underway.
Two proteins, one platform
Human lactoferrin follows the launch of LFX bovine lactoferrin earlier in 2026, making All G the only company with both in market.

The two share about 70% amino acid sequence identity, but suit different uses: human lactoferrin is drawing interest in women’s health and childhood nutrition, whereas bovine has proven benefits for immunity and gut health.
All G has filed multiple patents covering both production processes and applications.
The company has also produced recombinant micellar human caseins, a world first, and is developing human alpha-lactalbumin to enable infant formula built entirely on human milk proteins.
“Human lactoferrin is the first of many human milk proteins we will bring to market. We are leading the world in replicating the protein profile of human breast milk,” said Jan Pacas, CEO of All G.